Cuprina Holdings (Cayman) LTD
CUPR Nasdaq Orthopedic, Prosthetic & Surgical Appliances & Supplies Financials FY2022โFY2025
What Cuprina Holdings (Cayman) LTD does
No business description yet.
- Legal name
- Cuprina Holdings (Cayman) LTD
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F ยท Apr 27, 2026
- Accession ยท CIK
- 0001493152-26-019085
0001995704
Revenue and margins
Cuprina Holdings (Cayman) LTD had $0.0M of revenue in fiscal 2025, up 5.5% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was โ$7.0M in fiscal 2025, โ18,409.7% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Cuprina Holdings (Cayman) LTD returned โ to shareholders in fiscal 2025. The diluted share count rose 13.7%.
Balance sheet
Cash, debt and the ratios that show how comfortably Cuprina Holdings (Cayman) LTD can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | โ | $0.0M | $0.1M | $2.4M |
| Debt incl. finance leases | โ | โ | $0.2M | $0.1M |
| Debt / equity | โ | โ | โ | 0.0x |
| Interest coverage | โ655.8x | โ1,591.0x | โ947.2x | โ327.0x |
| Current ratio | โ | 0.3x | 0.3x | 2.4x |
| Quick ratio | โ | 0.3x | 0.3x | 2.4x |
| Total assets | โ | $1.2M | $1.3M | $6.6M |
| Total liabilities | โ | $3.4M | $4.6M | $2.7M |
| Shareholders' equity | โ$1.3M | โ$2.3M | โ$3.3M | $3.9M |
| Net debt (โ = net cash) | โ | โ | $0.1M | โ$2.3M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 5 | 2 / 8 | 4 / 9 |
| Accruals ratio | โ | โ13.9% | โ19.6% | 86.4% |
| Altman Z'' | โ | โ23.69 | โ32.23 | โ2.50 |
4 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.0M | $0.1M | $0.0M | $0.0M |
| Net interest income | โ$0.0M | โ$0.0M | โ$0.0M | โ$0.0M |
| Provision for credit losses | โ$0.0M | $0.0M | โ$0.0M | โ$0.0M |
| Gross profit | $0.0M | $0.0M | โ$0.0M | โ$0.0M |
| Research and development | $0.2M | $0.1M | $0.2M | $0.2M |
| Operating income | โ$0.9M | โ$0.8M | โ$1.2M | โ$3.7M |
| Interest expense | $0.0M | $0.0M | $0.0M | $0.0M |
| Pretax income | โ$0.8M | โ$0.8M | โ$1.1M | โ$3.5M |
| Net income | โ$0.8M | โ$0.8M | โ$1.2M | โ$3.6M |
| Diluted EPS | โ$4.41 | โ$4.63 | โ$6.50 | โ$17.47 |
| Diluted shares | 0.02B | 0.02B | 0.02B | 0.02B |
| Cash flow | ||||
| Cash from operations | โ$1.3M | โ$0.7M | โ$0.9M | โ$7.0M |
| Capital expenditure | $0.0M | $0.1M | $0.0M | $0.0M |
| Free cash flow | โ$1.4M | โ$0.7M | โ$0.9M | โ$7.0M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.0M |
| Balance sheet | ||||
| Cash and short-term investments | โ | $0.0M | $0.1M | $2.4M |
| Total debt | โ | โ | $0.2M | $0.1M |
| Current assets | โ | $1.1M | $1.2M | $5.7M |
| Current liabilities | โ | $3.4M | $4.4M | $2.4M |
| Inventory | โ | $0.0M | $0.0M | โ |
| Property and equipment, net | โ | $0.1M | $0.0M | $0.1M |
| Total assets | โ | $1.2M | $1.3M | $6.6M |
| Total liabilities | โ | $3.4M | $4.6M | $2.7M |
| Shareholders' equity | โ$1.3M | โ$2.3M | โ$3.3M | $3.9M |
| Margins | ||||
| Gross margin | 35.4% | 36.4% | โ6.4% | โ1.3% |
| Operating margin | โ2,079.5% | โ1,060.7% | โ3,401.4% | โ9,673.0% |
| EBITDA margin | โ2,028.0% | โ1,025.9% | โ3,314.1% | โ9,600.0% |
| Net margin | โ1,935.9% | โ1,111.5% | โ3,226.2% | โ9,359.7% |
| FCF margin | โ3,299.8% | โ956.0% | โ2,600.6% | โ18,409.7% |
| Net interest share of revenue | โ3.7% | โ56.1% | โ76.8% | โ29.6% |
| Returns | ||||
| Return on capital | โ | โ | โ | โ178.5% |
| Return on capital employed | โ | 37.0% | 39.1% | โ88.1% |
| Return on equity | โ | โ | โ | โ1,081.0% |
| Return on assets | โ | โ69.4% | โ94.2% | โ90.6% |
| Return on tangible equity | โ | โ | โ | โ90.9% |
| Growth | ||||
| Revenue growth | โ | 82.9% | โ51.7% | 5.5% |
| Share count change | โ | 0.0% | 0.0% | 13.7% |
| Financial health | ||||
| Debt / equity | โ | โ | โ | 0.0x |
| Interest coverage | โ655.8x | โ1,591.0x | โ947.2x | โ327.0x |
| Current ratio | โ | 0.3x | 0.3x | 2.4x |
| Quick ratio | โ | 0.3x | 0.3x | 2.4x |
| Capital allocation | ||||
| Capex / revenue | 28.3% | 67.5% | 45.3% | 116.5% |
| Quality scores | ||||
| Piotroski F-score | โ | โ | 2.0 | 4.0 |
| Altman Z'' | โ | โ23.7 | โ32.2 | โ2.5 |
| Accruals ratio | โ | โ13.9% | โ19.6% | 86.4% |
Source: SEC EDGAR XBRL filings (CIK 0001995704). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in SGD under US GAAP and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only โ not investment advice. Check the original filings before relying on any figure.